SETD7
C-terminal 6His-tagged recombinant, human SETD7 amino acids 1-366.
Biological information
Background
SETD7 (SET domain-containing protein 7) is a lysine methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the lysine 4 residue of histone H3 (H3K4), leading to the formation of monomethylated H3K4. SETD7 is a member of the SET domain-containing protein family and is the only known enzyme that specifically methylates H3K4 in a monomethylated form. SETD7 is dysregulated in various types of cancer, including breast cancer, prostate cancer, and hepatocellular carcinoma. Its dysregulation has been linked to aberrant gene expression, genome instability, and defects in DNA repair, which can contribute to the development and progression of cancer. SETD7 is an important epigenetic protein with potential therapeutic applications. Its inhibition has been shown to suppress tumor growth and improve insulin sensitivity in preclinical models of cancer and diabetes, respectively.
Target class
Epigenetic
Family
Accession number
NP_085151.1
Target Name
SETD7
Target Alias
Origin
Human
Theori. MW
41.5 kDa
Affinity tag
6His
Product specifications
Expression system
Expressed in E. coli
Purity
Refer to CoA for Purity
Purification method
Immobilised metal affinity chromatography
Sample Buffer
Protein in 5mM Tris/HCl pH7.5,
250mM NaCl, 65% Glycerol, 0.6mM TCEP. Frozen solution.
Specified activity
Refer to CoA
Application
For Research Only
Storage conditions
1 year at -70°C.
Usage disclaimer
For Research Only
Chemical data
Background
SETD7 (SET domain-containing protein 7) is a lysine methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the lysine 4 residue of histone H3 (H3K4), leading to the formation of monomethylated H3K4. SETD7 is a member of the SET domain-containing protein family and is the only known enzyme that specifically methylates H3K4 in a monomethylated form. SETD7 is dysregulated in various types of cancer, including breast cancer, prostate cancer, and hepatocellular carcinoma. Its dysregulation has been linked to aberrant gene expression, genome instability, and defects in DNA repair, which can contribute to the development and progression of cancer. SETD7 is an important epigenetic protein with potential therapeutic applications. Its inhibition has been shown to suppress tumor growth and improve insulin sensitivity in preclinical models of cancer and diabetes, respectively.
Compound name
Epigenetic
Catalog number
EPI056
Molecular formula
CAS
MW
Ka
Percent composition
Product specifications
Physical state
Purity (HPLC 214nm)
Retention time (RP18 HPLC)
CMC
Exact mass
Stability
For Research Only
Solubility structure
Datasheets
EPI056
Datasheet